News Novo Nordisk sheds billions in value on obesity data Novo Nordisk data on obesity candidate CagriSema falls short of expectations, wiping around $94 billion off its market valuation.
Digital Sponsored The AI effect in pharma commercial strategy: From data to re... Discover how AI is transforming the pharma commercial strategy. Unlock real-time insights & actions from data. Click here for more.
